Drug Profile
Lexatumumab
Alternative Names: Anti-TRAIL receptor-2 monoclonal antibody; Death receptor 5 monoclonal antibody; DR5 mAB; HGS-ETR2; TRAIL-R2 antibody; TRAIL-R2 human monoclonal antibody; TRAIL-R2 monoclonal antibodyLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Cambridge Antibody Technology
- Developer Human Genome Sciences
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; TRAIL receptor 2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 22 Apr 2009 Preclinical pharmacodynamics data presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR-2009)
- 16 Apr 2008 Human Genome Sciences reacquires rights to lexatumumab from GlaxoSmithKline
- 29 Oct 2007 Cambridge Antibody Technology has been integrated into MedImmune